- Home
- CLM vs AUPH Comparison
CLM vs AUPH Comparison
Compare CLM & AUPH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | CLM | AUPH |
|---|---|---|
| Founded | N/A | 1993 |
| Country | United States | Canada |
| Employees | N/A | N/A |
| Industry | Finance/Investors Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.2B | 2.2B |
| IPO Year | 1995 | 2014 |
Fundamental Metrics
Financial Performance| Metric | CLM | AUPH |
|---|---|---|
| Price | $7.47 | $16.13 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 4 |
| Target Price | N/A | ★ $17.25 |
| AVG Volume (30 Days) | 1.5M | ★ 1.9M |
| Earning Date | 01-01-0001 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 5075.00 |
| EPS | N/A | ★ 0.25 |
| Revenue | N/A | ★ $283,055,000.00 |
| Revenue This Year | N/A | $17.54 |
| Revenue Next Year | N/A | $15.74 |
| P/E Ratio | ★ N/A | $64.88 |
| Revenue Growth | N/A | ★ 20.38 |
| 52 Week Low | $6.92 | $8.32 |
| 52 Week High | $8.53 | $19.25 |
Technical Indicators
Market Signals| Indicator | CLM | AUPH |
|---|---|---|
| Relative Strength Index (RSI) | 48.28 | 48.18 |
| Support Level | $7.33 | $14.37 |
| Resistance Level | $7.79 | $19.25 |
| Average True Range (ATR) | 0.09 | 0.88 |
| MACD | 0.01 | -0.18 |
| Stochastic Oscillator | 47.54 | 22.29 |
Price Performance
Historical ComparisonAbout CLM Cornerstone Strategic Value Fund Inc. New
Cornerstone Strategic Value Fund Inc is a closed-end management investment company. The fund's objective is to seek long-term capital appreciation through investments in equity securities of U.S. and non-U.S. companies. It invests in various sectors, which include financials, information technology, healthcare, consumer discretionary, Consumer Staples, utilities, energy, Real Estate, materials, and other sectors.
About AUPH Aurinia Pharmaceuticals Inc
Aurinia Pharmaceuticals Inc is a biopharmaceutical company focused on delivering therapies to people living with autoimmune diseases with high unmet medical needs. The company developed LUPKYNIS (voclosporin), the first FDA-approved oral therapy for the treatment of adult patients with active lupus nephritis. It is also developing aritinercept, a dual inhibitor of B cell activating factor (BAFF) and a proliferation-inducing ligand (APRIL), for the potential treatment of autoimmune diseases.